Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BBOTthis companyBridgeBio Oncology Therapeutics Inc.	$2.16	-2.91×	0.95×	0×	-0.13×	414.3%	0.0%	0.0%	0.0%	-32.6%	-35.2%	-29.4%	0.01×	2.55×	0×	12.14×	0.0%	0	-0.72	3	B
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
KODKodiak Sciences Inc.	$105.57	-6.47×	9.45×	0×	-7.06×	-99.2%	0.0%	0.0%	0.0%	-146.1%	-73.7%	-9.2%	1.01×	0.25×	0×	4.72×	0.0%	1	7.23	1	D+
NRIXNurix Therapeutics, Inc.	$15.81	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
PHATPhathom Pharmaceuticals, Inc.	$5.41	-5.48×	-2.76×	6.91×	-8.47×	-248.1%	87.1%	-91.4%	-126.3%	50.5%	-125.2%	-13.8%	-0.48×	-0.54×	-2.35×	1.73×	0.0%	2	-4.79	2	C
SEPNSepterna Inc	$49.50	-25.35×	3.23×	26.85×	-24.05×	-147.7%	100.0%	-175.8%	-106.4%	-12.8%	-15.8%	8.9%	0.06×	2.05×	0×	4.73×	0.0%	3	6.86	2	C
Peer median	—	-6.47×	3.23×	6.91×	-7.06×	-213.0%	87.1%	-91.4%	-106.4%	-35.6%	-47.3%	-9.2%	0.1×	0.25×	0×	4.73×	0.0%	3	6.86	2	—